Drug Profile
OSI 754
Alternative Names: CP 609754; LNK-754Latest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Developer AstraZeneca; OSI Pharmaceuticals
- Class Antineoplastics; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Bladder cancer; Neurodegenerative disorders
Most Recent Events
- 03 Apr 2024 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
- 03 Apr 2024 Discontinued - Phase-I for Neurodegenerative disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO)